Home
ProgrammeThis year, the complicated travel conditions due geopolitical context led some international speakers to offer an online presentation, and at the same time, the number of remote registrations is much higher than in-person registrations, with few people expected to be on-site. Therefore, the organizing committee of the BPE Festival has decided to hold the event exclusively online. The whole team is working on a remote version that will maintain the usual conviviality of this annual event. We'll be back to you soon on this subject.
Since 2010, BPE has organized an annual scientific event dedicated to pharmacoepidemiology: the Bordeaux PharmacoEpi Festival.
World-class experts talk about a topic of their choice. This original master class format allows all participants to stay abreast of the major news in the discipline as well as hot topics in public health.
| Montse Soriano Gabarró Berlin, Germany |
Connecting and Innovating in Epidemiology, Pharmacoepidemiology and Public Health | |
| Julien Kirchgesner Paris, France |
Révolution numérique : Comment les données de santé en vraie vie transforment le traitement des maladies chroniques | |
| William Dixon Manchester, United Kingdom |
An excursion through exposures, outcomes and risk attribution | |
| Rishi J. Desai Boston, USA |
Advances in drug safety surveillance in the US FDA Sentinel program | |
| Maurizio Sessa Copenhagen, Denmark |
Revolutionizing Pharmacoepidemiology with AI: Exploring Current Applications with a Focus on Causal Machine Learning, Generative AI, Digital Twins, and Personalized Medicine | |
| Laure Carcaillon-Bentata Bordeaux, France |
Drug repurposing approaches in ageing and dementia research |
| Xabier García de Albéniz Barcelona, Spain |
Target Trial Emulation for Regulatory Real-World Evidence Generation | |
| Ursula Kirchmayer Rome, Italy |
Environment, climate and medications: new challenges in pharmacoepidemiology | |
| Patrice Verpillat Amsterdam, Netherlands |
How RWE is transforming regulatory decision making in Europe? | |
| Robert Platt Montreal, Canada |
Machine learning in pharmacoepidemiology: When, why, and how? | |
| John Seeger Boston, USA |
Effect Modification by Indication | |
| Antoine Pariente Bordeaux, France |
2010-2023 : évolution de l’utilisation des médicaments remboursés en France |
| Hedvig Nordeng Oslo, Norway |
European Initiative to Improve Knowledge about Medication Safety in Pregnancy and Lactation | |
| Andrea Margulis Barcelona, Spain |
Validation of events in database studies on pregnancy Pharmacoepidemiology | |
| Almut Winterstein Gainesville, USA |
Why design trumps analysis – pharmacoepidemiology in the era of big data and AI | |
| Anton Pottegård Odense, Denmark |
The future of (emergency) pharmacoepidemiology | |
| Tarry Ahuja Ottawa, Canada |
The Evolution of Drug Review in Canada – Integrating Innovation in HTA With Real-World Evidence | |
| Cécile Droz-Perroteau Bordeaux, France |
Pandémie et réseaux sociaux : la (pharmaco)-épidémiologie dans tous ses états (conférence grand public en français – public conference in french) |
| Daniel Prieto Alhambra Oxford, UK |
Tools for distributed network pharmacoepi studies | |
| Asieh Golozar Baltimore, USA |
Observational Cancer Research: Challenges and Opportunities | |
| Rodolphe Thiébaut Bordeaux, France |
Data science for vaccine development | |
| Vincent Lo Re Philadelphia, USA |
Opportunities and Challenges With Using Real-World Data to Conduct COVID-19 Pharmacoepidemiology Studies | |
| Vera Ehrenstein Aarhus N, Denmark |
Validation of routinely Collected Health Data (RCD) algorithms | |
| Nicholas Moore Bordeaux, France |
Des données de santé, mais pour quoi faire ? (conférence grand public en français – public conference in french) |
| Jeffrey Aronson Oxford, UK |
Clinical trials of therapeutic interventions during the covid-19 pandemic. | |
| Krista Huybrechtsn Boston, US |
Using Big Data to Inform Big Decisions regarding Medication Use in Pregnancy. | |
| Rosa Gini Florence, Italy |
Study variables in multi-database pharmacoepidemiology studies. | |
| Nicholas Moore Bordeaux, France |
Pharmacoepidemiology & Pharmacovigilance : The Next Chapter. | |
| Emmanuel Bacry Paris, France |
The French Health Data Hub. | |
| Christophe Tzourio Bordeaux, France & Yuan Ma Boston, US |
Brain under pressure: new markers of and targets for hypertension-related brain diseases. |
| Catherine Quantin Dijon, France |
The validity of diagnoses in public health databases (with invited speakers) | |
| Tania Schink Bremen, Germany |
Internal validation of outcomes in public health databases | |
| Giuseppe Traversa Rome, Italy |
Governing pharmaceutical care: Do we need to worry about the “excessive” prices of drugs? A pharmacoepidemiologist perspective | |
| Gianluca Trifiró Messine, Italy |
Challenges in postmarketing surveillance of biologics in the era of biosimilars | |
| Bernard Bégaud Bordeaux, France |
[General Public Conference] A quoi peut servir la pharmacoépidémiologie ? | |
| Kristian B. Filion Montreal, Canada |
The safety of antidiabetic drugs, and Distributed Drug Safety Networks/CNODES | |
| Ron Herings Amsterdam, NL |
Scenario and prediction modeling In pharmacoepidemiology for health personalization |
| Munir Pirmohammed Liverpool, UK |
The excitement and challenges of being a clinical pharmacologist | |
| Jacques Le Lorier Quebec, CA |
The Pharmacologically Pertinent Period of Effect. Are the editors doing their job ? | |
| Susana Perez-Gutthann Barcelona, Spain |
Looking behind the code | |
| Corinne de Vries London, UK |
Drug safety in pregnancy | |
| Tom Walley Liverpool, UK |
Clinical research in the UK | |
| John Ioannidis Stanford, USA |
Reproducible and useful epidemiology: why and how |
| Andy Stergachis Seattle, USA |
How to communicate benefits and risks, based on pharmacoepidemiological studies | |
| Jesper Hallas Odense, Denmark |
Pharmacovigilance in low- and middle-income countries: need, issues, methods, case studies, and future directions. | |
| Gerard de Pouvourville Paris, France |
Pharmacoeconomics in the modern world. | |
| Til Stürmer North Carolina, USA |
Principled versus pragmatic pharmacoepidemiology: do we need to take sides? | |
| Jaime Caro Boston, USA |
The use of DICE simulation for epidemiologic models | |
| Marc Rodwin Boston, USA |
1) How can inappropriate off-label drug use be managed? 2) Financial relations between pharmaceutical firms and physicians |
| Arnold Chan Taipei, Taiwan |
Pharmacoepidemiology and drug safety in Asia. | |
| Jerry Avorn Boston, USA |
Patients, doctors and drug safety | |
| Sonia Hernandez-Diaz Boston, USA |
Are babies the only outcomes in pregnancy? | |
| Stella Blackburn London, UK |
Considerations on risk-benefit assessment | |
| Bert Leufkens Utrecht, NL |
Pharmacovigilance is here to stay |
| Saad Shakir Boston, USA |
Risk Management in Pharmacovigilance: what is under the bonnet? | |
| Joshua Gagne Boston, USA |
Disease risk scores in pharmacoepidemiology? | |
| Patrick Ryan Philadelphia, USA |
Lessons in pharmacoepidemiology from the Observational Medical Outcomes Partnership | |
| Martijn Schuemie Rotterdam, NL |
More Lessons in pharmacoepidemiology from the Observational Medical Outcomes Partnership | |
| Morten Andersen Stockholm, Sweden |
How things happen in the Nordic countries? | |
| Darren Toh Boston, USA |
Prospective surveillance of newly approved medical products |
| Nancy Dreyer Boston, USA |
Observational Studies of Effectiveness and Safety: Practical Applications and Challenges | |
| Ken Rothman Boston, USA |
Ten Persistent Research Fallacies1. The randomized trial represents the perfect study design.2. Results from case-control studies are weaker than those from cohort studies, and the results from cohort studies are weaker than those from randomized trials.3. Study subjects should be representative of target populations.4. When measuring rates, the person-time of exposure to an agent goes in the denominator.5. The control group in ca-co studies should be just like the cases except that they don’t have disease. | |
| Ken Rothman Boston, USA |
Ten Persistent Research Fallacies (cont’d)6. When conducting multiple comparisons, take the number of comparisons into account when obtaining p-values.7. Account for missing data with an indicator term for “missingness” in a model8. A good way to categorize a variable is by quartiles or quintiles 9. A reasonable way to interpret data is by using significance tests10. Report power when reporting the results of a study. | |
| Samy Suissa Montreal, Canada |
Time-related biases in pharmacoepidemiology: Randomized trials built on sand. | |
| Jacques Benichou Rouen, France |
Attributable and competitive risks in pharmacoepidemiology |
| Syd Shapiro† Capetown, South Africa |
Oligognostic mega-analysis. Is Archie turning in his grave? | |
| Michal Abrahamowicz Montreal, Canada |
Modeling the effects of time-varying drug exposures: alternative models, cumulative effects and further challenges | |
| Olaf Klungel Utrecht, The Netherlands |
Improved control for confounding using propensityscores and instrumental variables | |
| Jeremy Rassen Boston, USA |
Computational pharmacoepi – the frontier between computing and PE | |
| Tobias Kurth Paris/Bordeaux, France |
The evaluation of different treatment effects in subgroups: practical uses of propensity scores | |
| Bernard Bégaud Bordeaux, France |
« Who cares about The truth? Non-comparative comparisons are safer », the Guru says. |
| Tom MacDonald Dundee, Scotland |
A rant about everything that irritates me including data protection, privacy, consent, regulation and ethics, interspersed with singing, art, poetry, philosophy (home-spun and otherwise), fantasy worlds (where are we now) and perfect worlds (will we ever get there?) a bit about risks (to individuals) and benefits (to society), duty of care, politics, changing the world, how we and ISPE can do this and other random thoughts including expressing ideas that are not my own or new and more singing”. | |
| Yola Moride Montreal – Canada |
Why do I bother doing teleconferences in the middle of the night for data safety monitoring boards when nobody cares about denominators? | |
| Stephen Evans London UK |
Pharmacoepidemiology and the pharmaceutical industry: undermined by their lawyers & tarnished by their funding? | |
| Judith K Jones Fairfax, Degge group, USA |
The smorgasboard of exposure options- drugs, biologics, vaccines, devices –how long do you count the biological effect in a population study…? | |
| Miriam Sturkenboom Rotterdam, NL |
The european database festival:one happy family? | |
| Alexander Walker Boston, USA |
Signal Detection |